Ticagrelor and central sleep apnoea: Impact of withdrawal and reintroduction.
Published in British journal of clinical pharmacology
Chronotherapy as a potential approach to hypertensive patients with elevated heart rate?
Published in British journal of clinical pharmacology
Ceftriaxone induced aplastic anaemia: A deadfall trap for bone marrow.
Published in British journal of clinical pharmacology
Reply to 'Hyperthermic intraperitoneal chemotherapy with oxaliplatin-Still not standard of care for patients with colore...
Published in British journal of clinical pharmacology
Optimising Low Dose Methotrexate for Rheumatoid Arthritis - A Review.
Published in British journal of clinical pharmacology
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intra-patient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population group...
Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Adverse Cardiovascular Events: A Population-based...
Published in British journal of clinical pharmacology
Sulfonylureas are recommended as second-line treatment in the management of type 2 diabetes. However, they are still commonly used also as first-line treatment instead of metformin. Given the controversial cardiovascular safety of sulfonylureas, we aimed to determine if their use as first-line treatment is associated with adverse cardiovascular eve...
New harmonized considerations on the evaluation instruments for baseline characterisation of frailty in the European Uni...
Published in British journal of clinical pharmacology
Sample size determination in bioequivalence studies using statistical assurance.
Published in British journal of clinical pharmacology
Bioequivalence (BE) trials aim to demonstrate that the 90%-CI of the T/R-ratio of the pharmacokinetic metrics between two formulations (Test-T and Reference-R) of a drug is fully included in the acceptance interval [0.80, 1.25]. Traditionally, the sample size of BE trials is based on a power calculation based on the intrasubject variability CV and ...
Statins popularity: A global picture.
Published in British journal of clinical pharmacology
Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.
Published in British journal of clinical pharmacology
